{"Q": 1, "answer": "no", "rationale": "The segment uses 'infectious', which is a factual description, not an intensified risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_4188", "batch_size": 260, "batch_pos": 91, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 2, "answer": "no", "rationale": "The segment describes factual activity related to surveillance.", "method": "llm_batch", "batch_id": "batch_2_16556", "batch_size": 260, "batch_pos": 78, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb paired with significant scale or impact.", "method": "llm_batch", "batch_id": "batch_3_11840", "batch_size": 260, "batch_pos": 13, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_14080", "batch_size": 260, "batch_pos": 256, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 5, "answer": "no", "rationale": "Reports facts about a network and testing.", "method": "llm_batch", "batch_id": "batch_5_14184", "batch_size": 260, "batch_pos": 253, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 6, "answer": "no", "rationale": "The segment describes a surveillance network scaling up testing across sites and states but lacks minimiser + scale contrast.", "method": "llm_batch", "batch_id": "batch_6_7576", "batch_size": 260, "batch_pos": 224, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_2480", "batch_size": 260, "batch_pos": 213, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 8, "answer": "yes", "rationale": "Describes implemented surveillance/monitoring action ('has begun scaling up H5-specific testing') without linking to current calm/safety.", "method": "llm_batch", "batch_id": "batch_8_19256", "batch_size": 260, "batch_pos": 119, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
